Trevi Therapeutics, Inc. (TRVI) Financial Analysis & Valuation | Quarter Chart
Trevi Therapeutics, Inc. (TRVI)
TRVIPrice: $13.19
Fair Value: 🔒
🔒score
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clin... more
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and... more
Description
Shares
| Market Cap | $1.69B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jennifer L. Good |
| IPO Date | 2019-05-07 | CAGR | — |
| Employees | 31 | Website | www.trevitherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TRVI chart loading...
Fundamentals
Technicals
| Enterprise Value | $2.12B | P/E Ratio | -41.22 |
| Forward P/E | -23.35 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 45.97 |
| P/CF Ratio | -199.71 | P/FCF Ratio | -259.63 |
| EPS | $-0.32 | EPS Growth 1Y | -32.02% |
| EPS Growth 3Y | -42.55% | EPS Growth 5Y | -82.35% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.27% | ROA | -0.24% |
| ROCE | -0.28% | Current Ratio | 19.66 |
| Quick Ratio | 19.66 | Cash Ratio | 1.94 |
| Debt/Equity | 0 | Interest Coverage | -51351 |
| Altman Z Score | 101.4 | Piotroski Score | 2 |